Drug intelligence / Profile preview

2'-deoxyuridine 5'-alpha,beta-imido-diphosphate

Development stage
Unknown
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01

Overview

**Description:** 2'-deoxyuridine 5'-alpha,beta-imido-diphosphate is a synthetic nucleotide analog belonging to the class of pyrimidine 2’-deoxyribonucleosides. It is structurally related to deoxyuridine diphosphate but features an imido (NH) linkage between the alpha and beta phosphate groups that renders it non-hydrolyzable by most enzymes. This property makes it valuable as a biochemical probe in studies of nucleotide metabolism and enzyme mechanisms involving nucleotides. The compound has been investigated for its potential applications in antiviral and anticancer therapy due to its ability to act as a stable substrate or inhibitor for enzymes such as dUTPase[1][3]. Its primary use remains experimental in research settings.

Other names
2′-DEOXYURIDINE 5′-α,β-IMIDO-DIPHOSPHATE[({[(2R,3S,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)amino]phosphonic acidC9H15N3O10P2 (chemical formula)
02

Targets

dUTPase (Deoxyuridine triphosphatase)

Beyond the preview

Go deeper on 2'-deoxyuridine 5'-alpha,beta-imido-diphosphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2'-deoxyuridine 5'-alpha,beta-imido-diphosphate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call